Health Safety: FDA Recalls Over 11,000 Bottles of a Hypertension Treatment
The U.S. Food and Drug Administration (FDA) recently relayed a major health alert initiated by the distributor Rising Pharma Holdings, Inc. This voluntary measure involves thousands of bottles of a frontline medication prescribed for high blood pressure. This incident highlights the ongoing challenges related to quality control within an increasingly globalized pharmaceutical supply chain, where rigorous checks are paramount for patient safety.
The recall, officially announced on June 5, 2026, specifically targets 11,460 bottles of Chlorthalidone Tablets USP 25 mg. These batches were manufactured in India by Inventia Healthcare Limited before being imported and distributed in the U.S. by Rising Pharma Holdings, Inc., a company based in New Jersey.
The cause of this extensive withdrawal lies in a failed dissolution test. Analyses revealed that the tablets from these specific batches do not disintegrate properly once ingested. This technical malfunction can lead to incomplete absorption of the active ingredient, thereby reducing the therapeutic efficacy of the treatment. For patients treated for cardiovascular conditions, uneven absorption of the antihypertensive drug compromises optimal blood pressure control. The FDA has categorized this incident as a "Class II Recall," meaning that while the risk of severe or medically reversible complications is low, temporary adverse health consequences are possible. To date, no serious adverse events have been reported in connection with these lots.
Patients and healthcare professionals are advised to identify and isolate the following batches:
100-count bottles: NDC 64980-599-01, Lot RISA24001
1,000-count bottles: NDC 64980-599-10, Lot RISB24002
Expiration date: April 2027 (04/2027)
This preventive recall serves as a reminder of the importance of continuous vigilance in managing chronic treatments. Patients currently taking Chlorthalidone should check the lot number and NDC printed on their bottle. If it matches the affected products, it is highly recommended to promptly contact a pharmacist or primary care physician to arrange a replacement. However, it is crucial never to stop hypertension medication without prior medical advice, as a sudden discontinuation can lead to immediate cardiovascular complications. For further information and official updates, the FDA website and Rising Pharma's guidelines remain the primary reference sources.